Seres Therapeutics, Inc.

NasdaqGS:MCRB Stock Report

Market Cap: US$154.6m

Seres Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Eric Shaff

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage21.7%
CEO tenure6yrs
CEO ownership0.1%
Management average tenure5.9yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

Nov 15
Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Aug 09
Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Dec 28
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Sep 01
Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Aug 19

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Aug 03

Seres Therapeutics: The Good And The Challenging

Jul 12

Seres Therapeutics stock slips on $100M stock offering

Jun 30

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Jun 16
Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Jun 09

Seres Therapeutics Is Playing A Long Game

Mar 06

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

CEO Compensation Analysis

How has Eric Shaff's remuneration changed compared to Seres Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$68m

Jun 30 2024n/an/a

-US$162m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$3mUS$685k

-US$114m

Sep 30 2023n/an/a

-US$224m

Jun 30 2023n/an/a

-US$153m

Mar 31 2023n/an/a

-US$265m

Dec 31 2022US$4mUS$662k

-US$250m

Sep 30 2022n/an/a

-US$231m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$87m

Dec 31 2021US$10mUS$625k

-US$66m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$132m

Mar 31 2021n/an/a

-US$105m

Dec 31 2020US$3mUS$590k

-US$89m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$76m

Mar 31 2020n/an/a

-US$66m

Dec 31 2019US$2mUS$540k

-US$70m

Sep 30 2019n/an/a

-US$73m

Jun 30 2019n/an/a

-US$78m

Mar 31 2019n/an/a

-US$95m

Dec 31 2018US$1mUS$435k

-US$99m

Compensation vs Market: Eric's total compensation ($USD3.16M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.

CEO

Eric Shaff (48 yo)

6yrs

Tenure

US$3,158,336

Compensation

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...

Leadership Team

NamePositionTenureCompensationOwnership
Eric Shaff
President6yrsUS$3.16m0.10%
$ 154.3k
Lisa von Moltke
Executive VP & Chief Medical Officer4.8yrsUS$1.57m0.019%
$ 29.4k
Teresa Young
Executive VP and Chief Commercial & Strategy Officer4.6yrsUS$1.82m0.053%
$ 81.9k
Marella Thorell
Executive VP & CFOless than a yearno datano data
Matthew Henn
Executive VP & Chief Scientific Officer5.9yrsUS$1.67m0.046%
$ 70.4k
Carlo Tanzi
Investor Relations Officer9.2yrsno datano data
Thomas DesRosier
Chief Legal Officer8.7yrsUS$1.44m0.079%
$ 122.4k
Caroline Holda
Assistant General Counselno datano datano data

5.9yrs

Average Tenure

57yo

Average Age

Experienced Management: MCRB's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Eric Shaff
President6yrsUS$3.16m0.10%
$ 154.3k
Willard Dere
Independent Director7.5yrsUS$225.23k0.019%
$ 28.7k
Dennis Ausiello
Independent Director9.8yrsUS$222.27k0%
$ 0
Kurt Graves
Independent Director9.2yrsUS$219.23k0%
$ 0
Richard Kender
Independent Director10.3yrsUS$232.69k0.037%
$ 57.5k
Mark Wilcox
Member of Scientific Advisory Board10yrsno datano data
Andrew Goodman
Member of Scientific Advisory Boardno datano datano data
Curtis Huttenhower
Member of Scientific Advisory Boardno datano datano data
Paul Biondi
Independent Director4.8yrsUS$211.73k0.028%
$ 43.1k
Stephen Berenson
Independent Chairman5.4yrsUS$249.23k0.0021%
$ 3.2k
Robert Jenq
Member of Scientific Advisory Boardno datano datano data
Elhanan Borenstein
Member of Scientific Advisory Boardno datano datano data

8.3yrs

Average Tenure

63yo

Average Age

Experienced Board: MCRB's board of directors are considered experienced (8.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 09:31
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Seres Therapeutics, Inc. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
John NewmanCanaccord Genuity
John TannerCantor Fitzgerald & Co.